pharma
Study: Med school pharma limits affect attitudes
Of late, academic medical centers have been instituting tough limits on pharmaceutical companies' relationship with their faculty and staff. On their face, the policies seem to be aimed primarily at... Read more...
Fight continues over state limits on prescription data mining
Hearings began this week on an effort, sponsored by at least six pharma data-mining firms, designed to overturn a new Maine law which lets prescribers opt out of having their prescribing information... Read more...
Amgen spending millions to fight CMS anemia drug limits
Hoping to get CMS to change its mind on new anemia drug reimbursement limits, Amgen is spending millions lobbying on Capitol Hill to gin up sentiment for an override. During the first six months of... Read more...
UPMC plans rollout of drugmaker relationship limits
The University of Pittsburgh Medical Center is planning the rollout of a newly-tough conflict-of-interest policy which would greatly curtail traditional relationships between its providers and... Read more...
Study: Drug, devicemaker ties with academic ctrs common
A new study suggests that academic medical centers have tight relationships with pharmas and medical-device makers, perhaps tighter than previously thought. The study, which was done by researchers... Read more...
SPOTLIGHT: Physician community site takes on Pfizer sponsorship
Physician community site takes on Pfizer sponsorshipWhen it was founded in September 2006, Sermo.com was intended to be a private place for physicians to discuss industry topics--including drug side... Read more...
NJ mulls pharma, device maker gift reporting
New Jersey's attorney general has created a task force to study whether the state should require disclosure of pharma and device-maker gifts to doctors. Attorney General Anne Milgram says she's aware... Read more...
SPOTLIGHT: Health plans target off-label use
Particularly given the rise of ultra-high-cost biologic drugs and other pricey treatments, health plans are intensifying their efforts to cut pharma costs. One way they're doing so, it seems, is to... Read more...
Bill would make drug, device maker payments public
The debate over pharma and device-maker payments has reached the U.S. Senate, where a bill requiring disclosure of nearly all of these arrangements is now under consideration. Right now, the F.D.A.... Read more...
FDA begins study of images in drug ads
Do images of happy, comfortable consumers with carefree lifestyles distract customers from what they really need to find out from drug ads? That's what the FDA would like to find out. The agency... Read more...
